Genomic Expression Inc

RNA platform for Next Generation Cures. By analyzing RNA we can detect disease, monitor health and design cures

  • Stage $1M in TTM Revenue
  • Industry Biotechnology
  • Location Boston, MA, US
  • Currency USD
  • Founded July 2017
  • Employees 7
  • Incorporation Type C-corp
  • Website genomicexpression.com

Company Summary

Commercial Stage RNA Platform For Next Generation Cures with a clinically validated and exponentially scalable platform that is disease agnostic.

By analyzing RNA we can detect disease, monitor health, and design next-generation cures.

The OneRNA® Platform enables rapid design and test of RNA Therapeutics and repurposing of existing drugs on an individual patient basis.

The OneRNA Platform is CLIA-validated in breast cancer and ovarian cancer ready for launch

Team

  • Morten Lorentz Pedersen
    CTO, PhD

    Inventor of the GEx's technologies
    PhD in Genetics at the JFK Institute
    Strong innovation track record

  • Gitte Pedersen
    CEO

    20+ years of management experience
    Deal resume north of $1 billion
    Master’s in Chemical Engineering

  • Jesper Zeuthen
    CMO, PhD

    Co-founder of GenMab & Topotarget
    Raised more than $650 for Bankinvest
    Karolinska, The Danish Cancer Society

  • Gitte Pedersen
    Lab Director, MD PHD | Medical Director

    Foundation Medicine, Quest, Invitae, Illumina

Advisors

  • Duane Morris LLP
    Lawyer
    Unconfirmed
    FullSky Partners
    Unconfirmed
    FullSky Partners
    Unconfirmed
  • Berdon, CPA
    Unconfirmed

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free